Meng Hu
Author directory2026
FDARxBench: Benchmarking regulatory and clinical reasoning on FDA generic drug assessment
Betty Xiong | Jillian Fisher | Benjamin Newman | Meng Hu | Shivangi Gupta | Yejin Choi | Lanyan Fang | Russ B Altman
Proceedings of the 2026 Conference on Empirical Methods in Natural Language Processing
Betty Xiong | Jillian Fisher | Benjamin Newman | Meng Hu | Shivangi Gupta | Yejin Choi | Lanyan Fang | Russ B Altman
Proceedings of the 2026 Conference on Empirical Methods in Natural Language Processing
We introduce an expert-guided, real-world benchmark for evaluating document-grounded question-answering (QA) motivated by generic drug assessment, using the U.S. Food and Drug Administration (FDA) drug label documents. Drug labels contain rich but heterogeneous clinical and regulatory information, making accurate question answering difficult for current language models. In collaboration with FDA regulatory assessors, we introduce FDARxBench, and construct a multi-stage pipeline for generating high-quality, expert-guided, LLM-assisted, QA examples spanning factual, multi-hop, and refusal tasks, and design evaluation protocols to assess both open-book and closed-book reasoning. Experiments across proprietary and open-weight models reveal substantial gaps in factual grounding, long-context retrieval, and safe refusal behavior. While motivated by FDA generic drug assessment needs, this benchmark also provides a substantial foundation for challenging regulatory-grade evaluation of label comprehension.